IPD’s 2025 Preview: 10 Pharmacy and Healthcare Trends to Anticipate

In this report, IPD Analytics’ Executive Clinical Pharmacy Team delves into 10 pharmacy and healthcare trends to anticipate for 2025, including notable drug approvals, advancements in treatment of rare diseases, oncology breakthroughs, GLP-1 receptor agonist (RA) affordability and access, and impacts expected from artificial intelligence (AI).

In 2025, IPD predicts there will be several noteworthy drug approvals, including indication expansions and first-time approvals for rare diseases. In addition, the report highlights potential biosimilar and generic approvals that we believe will have the most impact in the marketplace.

GLP-1 RAs will continue to be top of mind in 2025, and payers should be aware of possible upcoming approvals in the hereditary angioedema space, a high-cost area that has had little activity in recent years. The report also explores topics that are likely to impact payers in 2025, such as precision medicine, mental health, and AI.